title: [Severity of diabetic macular edema (DME) in Seine St Denis among patients treated by anti-VEGF].
abstract: BACKGROUND
  DME is the main cause of loss of vision over the course of diabetes. DME incidence is correlated with diabetes duration, high glycemic levels, high blood pressure, and the severity of diabetic retinopathy. To prevent DME, patients need to have access to medical care. In this study, we sought to know whether DME was more severe in Seine-Saint-Denis, a French area, where the poverty is higher than in other french places, and where the number of physicians is lower.
  
  
  METHODS
  We enrolled patients suffering from DME and treated by ranibizumab intravitreal injections between November 2012 and April 2013. In order to evaluate the severity of DME and the medical management of diabetes of these patients, we collected the following parameters: central macular thickness measured by SD-OCT, best corrected visual acuity, diabetic retinopathy severity, HbA1c, diabetes duration, type of diabetes, insulinotherapy, previous DME treatment and associated diseases.
  
  
  RESULTS
  We included 25 type 2 diabetic patients (8 women and 17 men), the mean age was 64±8.1 years. Mean central macular thickness was 523±145μm. The best corrected visual acuity was 45 letters at baseline (counting fingers-70 letters). Twenty-two patients (88%) had a severe non-proliferative diabetic retinopathy or a proliferative diabetic retinopathy. Mean HbA1c was 7.8% (±2.3%). For 23 cases (92%), diabetes was associated with high blood pressure. Sixty-four percent were treated by insulin. Diabetes lasted for 13.1 years at baseline.
  
  
  CONCLUSIONS
  Diabetic patients, in this case series, had a more severe DME regarding macular thickness and visual acuity than patients from large randomized studies found in the literature. This severity could be due to a sub-optimal management of their diabetes. DME may become a tool to identify patients with a limited access to good medical cares.
authors.affiliation: Service d'ophtalmologie, CHU Avicenne, 125, rue de Stalingrad, 93000 Bobigny, France. Electronic address: sofi.stephan@gmail.com.
authors.forename: S
authors.initials: S
authors.lastname: Stéphan
authors.affiliation: Service d'ophtalmologie, CHU Avicenne, 125, rue de Stalingrad, 93000 Bobigny, France.
authors.forename: F
authors.initials: F
authors.lastname: Fajnkuchen
authors.affiliation: Service d'ophtalmologie, CHU Avicenne, 125, rue de Stalingrad, 93000 Bobigny, France.
authors.forename: M
authors.initials: M
authors.lastname: Addou-Regnard
authors.affiliation: Service d'ophtalmologie, CHU Avicenne, 125, rue de Stalingrad, 93000 Bobigny, France.
authors.forename: T
authors.initials: T
authors.lastname: Grenet
authors.affiliation: Service d'ophtalmologie, CHU Avicenne, 125, rue de Stalingrad, 93000 Bobigny, France.
authors.forename: S
authors.initials: S
authors.lastname: Nghiem-Buffet
authors.affiliation: Service d'ophtalmologie, CHU Avicenne, 125, rue de Stalingrad, 93000 Bobigny, France.
authors.forename: G
authors.initials: G
authors.lastname: Chaine
authors.affiliation: Service d'ophtalmologie, CHU Avicenne, 125, rue de Stalingrad, 93000 Bobigny, France.
authors.forename: A
authors.initials: A
authors.lastname: Giocanti-Auregan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D003930:Diabetic Retinopathy / Q000453:epidemiology*; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D010820:Physicians / Q000600:supply & distribution; D011204:Poverty Areas; D000069579:Ranibizumab / Q000627:therapeutic use*; D012720:Severity of Illness Index; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab
keywords: Anti-VEGF; Diabetic macular edema; Diabetic retinopathy; Epidemiology; Ranibizumab; Rétinopathie diabétique; Épidémiologie; Œdème maculaire diabétique